Roche touts Phase 3 Susvimo data in diabetes-related ophthalmic diseases
Roche has unveiled new two-year data from late-stage studies of its ocular implant Susvimo in patients with diabetic eye conditions, as the Swiss pharma works …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.